A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non‑squamous non-small‑cell lung cancer

  • Authors:
    • Kyohei Kaburaki
    • Kazutoshi Isobe
    • Hiroshi Kobayashi
    • Takahiro Yoshizawa
    • Yujiro Takai
    • Sakae Homma
  • View Affiliations

  • Published online on: March 8, 2017     https://doi.org/10.3892/mco.2017.1187
  • Pages: 510-514
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this prospective study was to evaluate the efficacy and feasibility of bevacizumab combined with vinorelbine therapy in patients with previously treated non‑squamous non-small‑cell lung cancer (nonSq‑NSCLC). Patients who had received at least one prior chemotherapy course were eligible for this study. The patients were treated with vinorelbine (25 mg/kg on days 1 and 8) and bevacizumab (15 mg/kg on day 1), which was repeated every 3 weeks until the development of progressive disease or unacceptable toxicity. Between June, 2011 and January, 2013, 15 patients were enrolled. The response and disease control rates were 26.7 and 73.3%, respectively. The median progression-free survival was 2.1 months and the median overall survival was 34.1 months. Grade 3-4 phlebitis occurred in 3 patients. Therefore, the combination of vinorelbine and bevacizumab was found to be effective in patients with previously treated nonSq‑NSCLC, but physicians must be aware of the risk of phlebitis associated with this regimen.
View Figures
View References

Related Articles

Journal Cover

April 2017
Volume 6 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kaburaki, K., Isobe, K., Kobayashi, H., Yoshizawa, T., Takai, Y., & Homma, S. (2017). A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non‑squamous non-small‑cell lung cancer. Molecular and Clinical Oncology, 6, 510-514. https://doi.org/10.3892/mco.2017.1187
MLA
Kaburaki, K., Isobe, K., Kobayashi, H., Yoshizawa, T., Takai, Y., Homma, S."A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non‑squamous non-small‑cell lung cancer". Molecular and Clinical Oncology 6.4 (2017): 510-514.
Chicago
Kaburaki, K., Isobe, K., Kobayashi, H., Yoshizawa, T., Takai, Y., Homma, S."A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non‑squamous non-small‑cell lung cancer". Molecular and Clinical Oncology 6, no. 4 (2017): 510-514. https://doi.org/10.3892/mco.2017.1187